Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein Sells 1,066 Shares of Stock

Insmed Incorporated (NASDAQ:INSMGet Free Report) CFO Sara Bonstein sold 1,066 shares of Insmed stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.72, for a total value of $67,925.52. Following the completion of the sale, the chief financial officer now directly owns 118,863 shares in the company, valued at approximately $7,573,950.36. The trade was a 0.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sara Bonstein also recently made the following trade(s):

  • On Tuesday, January 7th, Sara Bonstein sold 3,470 shares of Insmed stock. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00.

Insmed Stock Down 0.7 %

Shares of NASDAQ:INSM opened at $65.25 on Friday. The business’s 50 day moving average is $71.23 and its 200 day moving average is $72.42. The stock has a market cap of $11.67 billion, a P/E ratio of -11.76 and a beta of 1.12. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSMGet Free Report) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. During the same quarter in the prior year, the company posted ($1.10) EPS. The company’s revenue for the quarter was up 18.1% on a year-over-year basis. Sell-side analysts predict that Insmed Incorporated will post -5.44 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on INSM shares. Truist Financial reissued a “buy” rating and issued a $105.00 price objective (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. HC Wainwright reissued a “buy” rating and set a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. JPMorgan Chase & Co. raised their price objective on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. Finally, Bank of America boosted their target price on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $83.67.

Get Our Latest Research Report on Insmed

Hedge Funds Weigh In On Insmed

Institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. raised its position in shares of Insmed by 672.7% in the 2nd quarter. Victory Capital Management Inc. now owns 147,140 shares of the biopharmaceutical company’s stock worth $9,858,000 after acquiring an additional 128,098 shares in the last quarter. Private Advisor Group LLC bought a new position in shares of Insmed during the 2nd quarter worth approximately $575,000. Los Angeles Capital Management LLC purchased a new stake in Insmed during the second quarter valued at approximately $258,000. ClariVest Asset Management LLC acquired a new stake in Insmed in the second quarter valued at approximately $738,000. Finally, American Century Companies Inc. grew its holdings in Insmed by 7.5% in the second quarter. American Century Companies Inc. now owns 755,271 shares of the biopharmaceutical company’s stock worth $50,603,000 after purchasing an additional 52,647 shares during the last quarter.

About Insmed

(Get Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Articles

Insider Buying and Selling by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.